Skip to content
10-Q

Quarterly Report

Adhera Therapeutics, Inc.

0001493152-22-031940

← back to feed
Filed
Nov 14, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2022 · Nov 14, 2022 3.16M sh
Stock Repurchased Q3 2022 · Sep 30, 2022 $2K
Cash And Equivalents Q3 2022 · Sep 30, 2022 $133K
Current Liabilities Q3 2022 · Sep 30, 2022 $22.06M
Current Liabilities Q3 2022 · Dec 31, 2021 $25.3M
Total Liabilities Q3 2022 · Sep 30, 2022 $22.06M
Total Liabilities Q3 2022 · Dec 31, 2021 $25.3M
Current Assets Q3 2022 · Sep 30, 2022 $256K
Current Assets Q3 2022 · Dec 31, 2021 $196K
Total Assets Q3 2022 · Sep 30, 2022 $256K
Total Assets Q3 2022 · Dec 31, 2021 $196K
Operating Cash Flow Q3 2022 · Sep 30, 2021 −$369K
Stockholders Equity Q3 2022 · Sep 30, 2021 −$20.24M
Stockholders Equity Q3 2022 · Jun 30, 2021 −$16.34M
Stockholders Equity restated Q3 2022 · Mar 31, 2021 −$15.51M
Stockholders Equity Q3 2022 · Dec 31, 2020 −$14.77M
Eps Basic Q3 2022 · Sep 30, 2021 −$6.38
Eps Basic Q3 2022 · Sep 30, 2021 −$10.83
Net Income Q3 2022 · Sep 30, 2021 −$3.74M
Net Income Q3 2022 · Sep 30, 2021 −$4.68M
Net Income Q3 2022 · Jun 30, 2021 −$514K
Net Income Q3 2022 · Mar 31, 2021 −$428K
Operating Income restated Q3 2022 · Sep 30, 2021 −$232K
Operating Income Q3 2022 · Sep 30, 2021 −$471K